HealthQuill Mirati Therapeutics
The US Food and Drug Administration has greenlighted Bristol Myers Squibb’s combination therapy to treat metastatic colorectal cancer in patients with a mutated gene.
Drugs Health Pharma

FDA gives nod to Bristol Myer’s colorectal cancer therapy

The US Food and Drug Administration has greenlighted Bristol Myers Squibb’s combination therapy to treat metastatic colorectal cancer in patients with a mutated.

Read More
Bristol Myers Squibb, one of the world’s largest pharmaceutical companies, will acquire Mirati Therapeutics for $5.8 billion through a combination of cash and debt to broaden its cancer portfolio.
Drugs Health Pharma

Bristol Myers acquires Mirati Therapeutics for $5.8 billion

HQ Team October 9, 2023: Bristol Myers Squibb, one of the world’s largest pharmaceutical companies, will acquire Mirati Therapeutics for $5.8 billion through.

Read More
X